Acute and severe acne in a patient treated with bevacizumab

Molina-Ruiz, Ana María; Dómine, Manuel; Requena, Luis

doi:10.1111/j.1365-4632.2012.5658.x

Cited by 10 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the reports suggest that during bevacizumab treatment, an acneiform eruption clinically and histopathologically may be observed as the cutaneous adverse effects . Retinoids have also been used in the systemic and topical treatment of various disorders, ranging from acne vulgaris to several types of cancer.…”

Section: Discussionmentioning

confidence: 99%

High resolution imaging of acne lesion development and scarring in human facial skin using OCT-based microangiography

Baran

Choi

et al. 2015

Lasers Surg. Med.

View full text Add to dashboard Cite

Background and Objective Acne is a common skin disease that often leads to scarring. Collagen and other tissue damage from the inflammation of acne give rise to permanent skin texture and microvascular changes. In this study, we demonstrate the capabilities of optical coherence tomography based microangiography in detecting high-resolution, three-dimensional structural and microvascular features of in vivo human facial skin during acne lesion initiation and scar development. Materials and Methods A real time swept source optical coherence tomography system is used in this study to acquire volumetric images of human skin. The system operates on a central wavelength of 1310 nm with an A-line rate of 100 kHz, and with an extended imaging range (~12 mm in air). The system uses a handheld imaging probe to image acne lesion on a facial skin of a volunteer. We utilize optical microangiography (OMAG) technique to evaluate the changes in microvasculature and tissue structure. Results Thanks to the high sensitivity of OMAG, we are able to image microvasculature up to capillary level and visualize the remodeled vessels around the acne lesion. Moreover, vascular density change derived from OMAG measurement is provided as an alternative biomarker for the assessment of human skin diseases. In contrast to other techniques like histology or microscopy, our technique made it possible to image 3D tissue structure and microvasculature up to 1.5 mm depth in vivo without the need of exogenous contrast agents. Conclusion The presented results are promising to facilitate clinical trials aiming to treat acne lesion scarring, as well as other prevalent skin diseases, by detecting cutaneous blood flow and structural changes within human skin in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

High resolution imaging of acne lesion development and scarring in human facial skin using OCT-based microangiography

Baran

Choi

et al. 2015

Lasers Surg. Med.

View full text Add to dashboard Cite

show abstract

“…Several groups have reported ulceration, bleeding, and necrosis of striae distensae associated with bevacizumab 264–267 . Dermatologic toxicities to bevacizumab include maculopapular or acneiform eruptions 268–273 . The literature contains case reports of cutaneous lupus associated with bevacizumab, which histopathologically exhibits interface dermatitis with occasional neutrophils 53,54 .…”

Section: Resultsmentioning

confidence: 99%

“…[264][265][266][267] Dermatologic toxicities to bevacizumab include maculopapular or acneiform eruptions. [268][269][270][271][272][273] The literature contains case reports of cutaneous lupus associated with bevacizumab, which histopathologically exhibits interface dermatitis with occasional neutrophils. 53,54 Other cAE include perforating dermatosis, histopathologically showing irregular epidermal acanthosis, collagen accumulation in the dermal papillae, and keratotic corneal plugs.…”

Section: Vegf/vegfrmentioning

confidence: 99%

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

et al. 2022

View full text Add to dashboard Cite

Background Since their first approval 25 years ago, monoclonal antibodies (mAbs) have become important targeted cancer therapeutics. However, dermatologic toxicities associated with non−immune checkpoint inhibitor (non‐ICI) mAbs may complicate the course of cancer treatment. Data on the incidence and types of these reactions are limited. Methods A comprehensive review was conducted on dermatologic toxicities associated with different classes of non‐ICI mAbs approved for treatment of solid tumors and hematologic malignancies. The review included prospective Phase 1, 2, and 3 clinical trials; retrospective literature reviews; systematic reviews/meta‐analyses; and case series/reports. Results Dermatologic toxicities were associated with several types of non‐ICI mAbs. Inflammatory reactions were the most common dermatologic toxicities, manifesting as maculopapular, urticarial, papulopustular/acneiform, and lichenoid/interface cutaneous adverse events (cAEs) with non‐ICI mAbs. Immunobullous reactions were rare and a subset of non‐ICI mAbs were associated with the development of vitiligo cAEs. Conclusion Dermatologic toxicities of non‐ICI mAbs are diverse and mostly limited to inflammatory reactions. Awareness of the spectrum of the histopathologic patterns of cAE from non‐ICI mAbs therapy is critical in the era of oncodermatology and oncodermatopathology.

show abstract

“…Similar reactions have already been described in the literature following systemic mAb administration: leucocytoclastic vasculitis has been related to infliximab (anti-tumor necrosis factor (TNF) mAb) [24], erythroderma secondary to tocilizumab (humanized anti-human interleukin 6 receptor (IL-6R) antibody) [25] and maculopapular rash after anti-TNF mAb [19]. In particular, systemic use of anti-VEGFs in oncology has also been reported to induce cutaneous adverse events, including unspecified skin rash, exfoliative dermatitis and acute and severe acne [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors

Moret

Ambresin

Gianniou

et al. 2021

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To describe a series of non-immediate drug hypersensitivity reactions after intravitreal anti-vascular endothelial growth factors (anti-VEGFs). Patients and methods Retrospective report of 6 patients with cutaneous non-immediate drug hypersensitivity reactions following intravitreal anti-VEGF injections, 4 after ranibizumab, 1 after bevacizumab and 1 after aflibercept. Results Clinical manifestations ranged from mild maculopapular rash, purpura to severe generalized erythroderma, with or without systemic involvement such as microscopic hematuria and proteinuria or fever. In two out of the six patients, reintroduction of either the same or an alternative anti-VEGF drug did induce a recurrence of the drug hypersensitivity reaction, while 4 patients showed no recurrence. Conclusion Cutaneous non-immediate drug hypersensitivity reactions secondary to intravitreal anti-VEGF may occur. Continuation of the same drug or switch to another anti-VEGF may either induce recurrence or be well supported by the patient. The decision of drug discontinuation should be guided by the severity of the disease.

show abstract

Acute and severe acne in a patient treated with bevacizumab

Cited by 10 publications

References 20 publications

High resolution imaging of acne lesion development and scarring in human facial skin using OCT-based microangiography

High resolution imaging of acne lesion development and scarring in human facial skin using OCT-based microangiography

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors

Contact Info

Product

Resources

About